In a SMA mouse model, the chromatin-modifying compound VPA, which is approved by FDA for human treatment, has been shown, by improving SMN2 exon 7 inclusion, to counteract the unexpected negative effect that ASOs have on chromatin [15]. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.